Potency of Full-Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations.

Janssen JA, Hofland LJ, Strasburger CJ, van den Dungen ES, Thevis M

PloS one18 Mar 2016Cited by 6 (Europe PMC)

PMID26991004PMCIDPMC4798685DOI10.1371/journal.pone.0150453PepBankPUB-26991004

Summary

AimsTo compare full-length mechano growth factor (full-length MGF) with human recombinant insulin-like growth factor-I (IGF-I) and human recombinant insulin (HI) in their ability to activate the human IGF-I receptor (IGF-IR), the human insulin receptor (IR-A) and the human insulin receptor-B (IR-B), respectively. In addition, we tested the stimulatory activity of human MGF and its stabilized analog Goldspink-MGF on the IGF-IR.MethodsThe effects of full-length MGF, IGF-I, human mechano growth factor (MGF), Goldspink-MGF and HI were compared using kinase specific receptor activation (KIRA) bioassays specific for IGF-I, IR-A or IR-B, respectively. These assays quantify activity by measuring auto-phosphorylation of the receptor upon ligand binding.ResultsIGF-IR: At high equimolar concentrations maximal IGF-IR stimulating effects generated by full-length MGF were similar to that of IGF-I (89-fold vs. 77-fold, respectively). However, EC50 values of IGF-I and full-length MGF for the IGF-I receptor were 0.86 nmol/L (95% CI 0.69-1.07) and 7.83 nmol/L (95% CI: 4.87-12.58), respectively. No IGF-IR activation was observed by human MGF and Goldspink-MGF, respectively. IR-A/IR-B: At high equimolar concentrations similar maximal IR-A stimulating effects were observed for full -length MGF and HI, but maximal IR-B stimulation achieved by full -length MGF was stronger than that by HI (292-fold vs. 98-fold). EC50 values of HI and full-length MGF for the IR-A were 1.13 nmol/L (95% CI 0.69-1.84) and 73.11 nmol/L (42.87-124.69), respectively; for IR-B these values were 1.28 nmol/L (95% CI 0.64-2.57) and 35.10 nmol/L (95% 17.52-70.33), respectively.ConclusionsFull-length MGF directly stimulates the IGF-IR. Despite a higher EC50 concentration, at high equimolar concentrations full-length MGF showed a similar maximal potency to activate the IGF-IR as compared to IGF-I. Further research is needed to understand the actions of full-length MGF in vivo and to define the physiological relevance of our in vitro findings.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cell-free)Activity measurement
At high equimolar concentrations, full-length MGF produced maximal IGF-I receptor stimulation similar to that of IGF-I.
In plain wordsIn lab tests, full-length MGF switched on the IGF-I receptor about as strongly as IGF-I at high equal amounts.
Peptide
MGF / PEG-MGF
Outcome
No significant changeMaximal IGF-I receptor stimulation by full-length MGF
Study
n: not reported in source
KIRA receptor-activation bioassay
Comparator
IGF-I
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Measurements
maximal IGF-IR stimulation
89 fold
full-length MGF
maximal IGF-IR stimulation
77 fold
IGF-I
Source sentences
Summary
IGF-IR: At high equimolar concentrations maximal IGF-IR stimulating effects generated by full-length MGF were similar to that of IGF-I (89-fold vs. 77-fold, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of full-length MGF, IGF-I, human mechano growth factor (MGF), Goldspink-MGF and HI were compared using kinase specific receptor activation (KIRA) bioassays specific for IGF-I, IR-A or IR-B, respectively.
Show in the study text Report a problemFND-2699100401
02LabIn vitro (cell-free)Activity measurement
The EC50 of full-length MGF at the IGF-I receptor was higher than that of IGF-I.
In plain wordsIn lab tests, full-length MGF needed a higher concentration than IGF-I to activate the IGF-I receptor.
Peptide
MGF / PEG-MGF
Outcome
Not applicableEC50 at the IGF-I receptor
Study
n: not reported in source
KIRA receptor-activation bioassay
Comparator
IGF-I
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Measurements
EC50
7.83 nmol/L
full-length MGF, IGF-IR
EC50
0.86 nmol/L
IGF-I, IGF-IR
Source sentences
Summary
However, EC50 values of IGF-I and full-length MGF for the IGF-I receptor were 0.86 nmol/L (95% CI 0.69-1.07) and 7.83 nmol/L (95% CI: 4.87-12.58), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of full-length MGF, IGF-I, human mechano growth factor (MGF), Goldspink-MGF and HI were compared using kinase specific receptor activation (KIRA) bioassays specific for IGF-I, IR-A or IR-B, respectively.
Show in the study text Report a problemFND-2699100402
03LabIn vitro (cell-free)Activity measurement
Human MGF and Goldspink-MGF did not activate the IGF-I receptor.
In plain wordsIn lab tests, the shorter human MGF and Goldspink-MGF forms did not activate the IGF-I receptor.
Peptide
MGF / PEG-MGF
Outcome
No significant changeIGF-I receptor activation by human MGF and Goldspink-MGF
Study
n: not reported in source
KIRA receptor-activation bioassay
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
No IGF-IR activation was observed by human MGF and Goldspink-MGF, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of full-length MGF, IGF-I, human mechano growth factor (MGF), Goldspink-MGF and HI were compared using kinase specific receptor activation (KIRA) bioassays specific for IGF-I, IR-A or IR-B, respectively.
Show in the study text Report a problemFND-2699100403
04LabIn vitro (cell-free)Activity measurement
At high equimolar concentrations, full-length MGF and human insulin had similar maximal IR-A stimulating effects.
In plain wordsIn lab tests, full-length MGF and insulin switched on insulin receptor A about equally at high equal amounts.
Peptide
MGF / PEG-MGF
Outcome
No significant changeMaximal insulin receptor A stimulation
Study
n: not reported in source
KIRA receptor-activation bioassay
Comparator
Human insulin
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
At high equimolar concentrations similar maximal IR-A stimulating effects were observed for full -length MGF and HI
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of full-length MGF, IGF-I, human mechano growth factor (MGF), Goldspink-MGF and HI were compared using kinase specific receptor activation (KIRA) bioassays specific for IGF-I, IR-A or IR-B, respectively.
Show in the study text Report a problemFND-2699100404
05LabIn vitro (cell-free)Activity measurement
Maximal IR-B stimulation by full-length MGF was stronger than that by human insulin.
In plain wordsIn lab tests, full-length MGF switched on insulin receptor B more strongly than insulin did.
Peptide
MGF / PEG-MGF
Outcome
IncreaseMaximal insulin receptor B stimulation
Study
n: not reported in source
KIRA receptor-activation bioassay
Comparator
Human insulin
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Measurements
maximal IR-B stimulation
292 fold
full-length MGF
maximal IR-B stimulation
98 fold
human insulin
Source sentences
Summary
but maximal IR-B stimulation achieved by full -length MGF was stronger than that by HI (292-fold vs. 98-fold).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of full-length MGF, IGF-I, human mechano growth factor (MGF), Goldspink-MGF and HI were compared using kinase specific receptor activation (KIRA) bioassays specific for IGF-I, IR-A or IR-B, respectively.
Show in the study text Report a problemFND-2699100405
06LabIn vitro (cell-free)Activity measurement
The EC50 of full-length MGF at IR-A was higher than that of human insulin.
In plain wordsIn lab tests, full-length MGF needed a higher concentration than insulin to activate insulin receptor A.
Peptide
MGF / PEG-MGF
Outcome
Not applicableEC50 at insulin receptor A
Study
n: not reported in source
KIRA receptor-activation bioassay
Comparator
Human insulin
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Measurements
EC50
73.11 nmol/L
full-length MGF, IR-A
EC50
1.13 nmol/L
human insulin, IR-A
Source sentences
Summary
EC50 values of HI and full-length MGF for the IR-A were 1.13 nmol/L (95% CI 0.69-1.84) and 73.11 nmol/L (42.87-124.69), respectively
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of full-length MGF, IGF-I, human mechano growth factor (MGF), Goldspink-MGF and HI were compared using kinase specific receptor activation (KIRA) bioassays specific for IGF-I, IR-A or IR-B, respectively.
Show in the study text Report a problemFND-2699100406
07LabIn vitro (cell-free)Activity measurement
The EC50 of full-length MGF at IR-B was higher than that of human insulin.
In plain wordsIn lab tests, full-length MGF needed a higher concentration than insulin to activate insulin receptor B.
Peptide
MGF / PEG-MGF
Outcome
Not applicableEC50 at insulin receptor B
Study
n: not reported in source
KIRA receptor-activation bioassay
Comparator
Human insulin
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Measurements
EC50
35.1 nmol/L
full-length MGF, IR-B
EC50
1.28 nmol/L
human insulin, IR-B
Source sentences
Summary
EC50 values of HI and full-length MGF for the IR-A were 1.13 nmol/L (95% CI 0.69-1.84) and 73.11 nmol/L (42.87-124.69), respectively; for IR-B these values were 1.28 nmol/L (95% CI 0.64-2.57) and 35.10 nmol/L (95% 17.52-70.33), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of full-length MGF, IGF-I, human mechano growth factor (MGF), Goldspink-MGF and HI were compared using kinase specific receptor activation (KIRA) bioassays specific for IGF-I, IR-A or IR-B, respectively.
Show in the study text Report a problemFND-2699100407

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.